Paris - Delayed Quote ? EUR Adocia SA (ADOC.PA) Follow Compare 7.49 +1.30 (+21.00%) At close: October 18 at 5:35 PM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations ADOCIA Announces Patenting Stable Combinations of GLP-1 and Amylin Analogs for the Treatment of Obesity and Diabetes Using Its BioChaperone? Platform LYON, France, October 15, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 - ADOC), a clinical-stage biopharmaceutical company specialized in the discovery and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it has filed patents of stable formulations of hormone combinations for the treatment of obesity and diabetes using its BioChaperone? platform. Business Wire ? 5 days ago ADOC.PA +21.00% Number of Shares and Voting Rights of ADOCIA as of September 30th, 2024 LYON, France, October 08, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French ? Code de Commerce ? and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions Business Wire ? 12 days ago ADOC.PA +21.00% ADOCIA Announces Appointment of Mathieu?William Gilbert as Chief Financial Officer LYON, France, September 23, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the appointment of Mathieu-William Gilbert as Chief Financial Officer. He succeeds Valérie Danaguezian, who has held this position since 2005. Business Wire ? 27 days ago ADOC.PA +21.00% Number of Shares and Voting Rights of ADOCIA as of August 31st, 2024 LYON, France, September 20, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French ? Code de Commerce ? and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutio Business Wire ? 30 days ago ADOC.PA +21.00% ADOCIA Announces First Half 2024 Financial Results and Provides a Business Update LYON, France, September 19, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces today its financial results for the six months period ended June 30th, 2024, and provides a business update. Business Wire ? last month ADOC.PA +21.00% Number of Shares and Voting Rights of ADOCIA as of July 31st, 2024 LYON, France, August 30, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French ? Code de Commerce ? and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions Business Wire ? last month ADOC.PA +21.00% ADOCIA to Deliver Oral Presentations on AdoShell? and AdoGel? at EASD Annual Meeting LYON, France, August 29, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced oral presentations at EASD 2024, unveiling the latest results obtained on AdoShell? Islets, an immunoprotective hydrogel containing islets of Langerhans for the treatment of diabetes by cell therapy, and on AdoGel Business Wire ? last month ADOC.PA +21.00% ADOCIA Reports Second Quarter 2024 Financial Results and Provides a Business Update LYON, France, July 24, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2024 and provides a business update. Business Wire ? 2 months ago ADOC.PA +21.00% ADOCIA Announces Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets LYON, France, July 19, 2024--Regulatory News: Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on June 30th 2024 : Business Wire ? 3 months ago ADOC.PA +21.00% Number of Shares and Voting Rights of ADOCIA as of June 30th, 2024 LYON, France, July 11, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French ? Code de Commerce ? and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions fo Business Wire ? 3 months ago ADOC.PA +21.00% ADOCIA Announces That Tonghua Dongbao Is Discontinuing One of the Two Partnership Programs: BioChaperone? Combo LYON, France, July 10, 2024--ADOCIA Announces that Tonghua Dongbao is Discontinuing one of the two Partnership Programs: BioChaperone? Combo Business Wire ? 3 months ago ADOC.PA +21.00% ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions LYON, France, June 18, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, is pleased to announce that exclusive data from three of Adocia’s innovative technology platforms have been selected for poster presentations at the upcoming American Diabetes Association’s (ADA) 84th Scientific Sessions to be held J Business Wire ? 4 months ago ADOC.PA +21.00% Number of Shares and Voting Rights of ADOCIA as of May 31st, 2024 LYON, France, June 17, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French ? Code de Commerce ? and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions fo Business Wire ? 4 months ago ADOC.PA +21.00% ADOCIA Confirms Its Eligibility for the PEA–PME LYON, France, June 06, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, confirms its eligibility for the "PEA – PME" stock savings tax regime, which decree has been published in the French Journal Officiel on March 4, 2014 (Decree n ° 2014-283), and which entered into force on March 6, 2014. Business Wire ? 4 months ago ADOC.PA +21.00% ADOCIA Announces Appointment of Mathieu?William Gilbert as Chief Operating Officer LYON, France, June 03, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the appointment of Mathieu-William Gilbert as Chief Operating Officer (COO). Business Wire ? 4 months ago ADOC.PA +21.00% ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 13th, 2024 in Paris LYON, France, May 23, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it will hold its annual shareholders’ meeting ("AGM") on June 13th, 2024, at 10:30 am, in the Jones Day’s offices, Hotel de Talleyrand, 2 rue Saint Florentin, 75001 Paris. Business Wire ? 4 months ago ADOCY Number of Shares and Voting Rights of ADOCIA as of April 30th, 2024 LYON, France, May 15, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French ? Code de Commerce ? and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for Business Wire ? 5 months ago ADOCY ADOCIA Reports First Quarter 2024 Financial Results and Provides a Business Update LYON, France, May 14, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2024 and provides a business update. Business Wire ? 5 months ago ADOCY ADOCIA Announces the Release of Its Universal Registration Document for the Year 2023 LYON, France, April 29, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today the filing of its 2023 Universal Registration Document with the "Autorité des marchés financiers" (AMF - the French financial markets regulator) on April 29, 2024. Business Wire ? 5 months ago ADOCY ADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial Update LYON, France, April 24, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces today its annual financial results as of December 31, 2023. The consolidated financial statements contained herein were approved by Adocia’s board of directors on April 23, 2024. These statements will be presented to share Business Wire ? 5 months ago ADOCY Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is CAC 40 Return ADOC.PA CAC 40 YTD -35.10% +0.93% 1-Year -2.73% +8.30% 3-Year -24.34% +13.16%
